Recursion Pharmaceuticals, Inc. (RXRX)
3.185
-0.14
(-4.35%)
USD |
NASDAQ |
Nov 13, 16:00
3.16
-0.02
(-0.78%)
After-Hours: 19:59
Recursion Pharmaceuticals Enterprise Value : 1.305B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.305B |
| November 12, 2026 | 1.387B |
| November 11, 2026 | 1.532B |
| November 10, 2026 | 1.510B |
| November 09, 2026 | 1.653B |
| November 06, 2026 | 1.493B |
| November 05, 2026 | 1.482B |
| November 04, 2026 | 1.695B |
| November 03, 2026 | 1.583B |
| November 02, 2026 | 1.667B |
| October 30, 2026 | 1.779B |
| October 29, 2026 | 1.897B |
| October 28, 2026 | 1.959B |
| October 27, 2026 | 1.791B |
| October 26, 2026 | 1.650B |
| October 23, 2026 | 1.594B |
| October 22, 2026 | 1.527B |
| October 21, 2026 | 1.560B |
| October 20, 2026 | 1.572B |
| October 19, 2026 | 1.544B |
| October 16, 2026 | 1.462B |
| October 15, 2026 | 1.852B |
| October 14, 2026 | 1.617B |
| October 13, 2026 | 1.670B |
| October 12, 2026 | 1.768B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.964B |
| October 08, 2026 | 1.734B |
| October 07, 2026 | 1.914B |
| October 06, 2026 | 2.116B |
| October 05, 2026 | 2.200B |
| October 02, 2026 | 1.830B |
| October 01, 2026 | 1.802B |
| September 30, 2026 | 1.835B |
| September 29, 2026 | 1.668B |
| September 28, 2026 | 1.492B |
| September 25, 2026 | 1.513B |
| September 24, 2026 | 1.593B |
| September 23, 2026 | 1.492B |
| September 22, 2026 | 1.679B |
| September 21, 2026 | 1.636B |
| September 18, 2026 | 1.561B |
| September 17, 2026 | 1.406B |
| September 16, 2026 | 1.219B |
| September 15, 2026 | 1.246B |
| September 14, 2026 | 1.337B |
| September 11, 2026 | 1.225B |
| September 10, 2026 | 1.203B |
| September 09, 2026 | 1.233B |
| September 08, 2026 | 1.353B |
| September 04, 2026 | 1.454B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Absci Corp. | 1.286B |
| Editas Medicine, Inc. | 214.00M |
| Twist Bioscience Corp. | 6.507B |
| Beam Therapeutics, Inc. | 1.562B |
| AbbVie, Inc. | 591.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -119.04M |
| Revenue (Quarterly) | 18.55M |
| Total Expenses (Quarterly) | 137.59M |
| EPS Diluted (Quarterly) | -0.2192 |
| Gross Profit Margin (Quarterly) | -9.13% |
| Profit Margin (Quarterly) | -641.6% |
| Earnings Yield | -28.02% |
| Normalized Earnings Yield | -28.02 |